Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

BCAL Diagnostics Targets November Launch After Breast Test Validation

BDX: $0.084 +5.00% · MC: $22M

BCAL Diagnostics completed clinical validation of BREASTESTplus 2 for women aged 30 and over across all breast densities, with a launch targeted for November subject to accreditation and operational readiness. Avantect Multicancer is now available at select Sydney and Melbourne locations, while preparations continue for a broader rollout. BCAL also increased its strategic interest in Genetic Signatures to approximately 18%, acquiring additional shares for $2 million.

Source announcements: 2026-10-30 11:40 to 2026-10-30 11:40 Sydney time
Story updated 2026-10-30 11:43 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments